Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378482 · ClinicalTrials.gov registry record · Phase 2
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00378482 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 37 participants.
The verdict
NCT00378482, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
Interventions
- DRUG CP-675,206 (Tremelimumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-03-05 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378482
The ClinicalTrials.gov registry entry for NCT00378482 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-675,206 (Tremelimumab) is the first listed.
NCT00378482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00378482 about?
NCT00378482 is a clinical study titled "A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.". This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
What is the current status of trial NCT00378482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2007-03-05. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT00378482?
The interventions under investigation include: CP-675,206 (Tremelimumab) (DRUG).
Who is sponsoring clinical trial NCT00378482?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.